LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced its intention to offer, subject to market and other conditions, up to $250 million aggregate principal amount of its Convertible Senior Notes due 2017. The notes will be convertible, under certain circumstances, into cash, shares of Cubist’s common stock, or a combination, at Cubist’s election. The interest rate, conversion price, and certain other terms of the offering are to be determined at the time of pricing. Cubist intends to grant the underwriters an option to purchase up to an additional $37.5 million aggregate principal amount of notes.
